<DOC>
	<DOCNO>NCT02061709</DOCNO>
	<brief_summary>The purpose study determine whether Ragweed-SPIRE safe effective reduce allergy symptom people suffer allergy Ragweed pollen</brief_summary>
	<brief_title>Evaluating Efficacy Ragweed-SPIRE Following Exposure Ragweed Allergen Environmental Exposure Chamber</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<criteria>Male female , age 1865 year . Reliable history consistent moderate severe rhinoconjunctivitis exposure ragweed least previous two season . Minimum qualify rhinoconjunctivitis symptom score Ragweedspecific Immunoglobulin E ( IgE ) &gt; 0.70 kU/L . Subjects history ragweed pollen induce asthma A history anaphylaxis ragweed allergen . FEV1 &lt; 80 % predict . Subjects tolerate Baseline Challenge EEC . Subjects administration epinephrine contraindicate ( e.g . subject acute chronic symptomatic coronary heart disease severe hypertension ) . History immunopathological disease ( e.g . multiple sclerosis ) opinion Investigator Sponsor could interfere result obtain study . A history severe drug allergy , severe angioedema anaphylactic reaction food . A history significant disease disorder ( e.g . cardiovascular , pulmonary , gastrointestinal , liver , renal , neurological , musculoskeletal , endocrine , metabolic , neoplastic/malignant , psychiatric , major physical impairment )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Rhinoconjunctivitis</keyword>
	<keyword>Rhinitis</keyword>
	<keyword>Seasonal</keyword>
	<keyword>Ragweed</keyword>
	<keyword>Allergy</keyword>
</DOC>